Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations

B Paes, I Mitchell, A Li, K L Lanctôt, B Paes, I Mitchell, A Li, K L Lanctôt

Abstract

Palivizumab utilization, compliance, and outcomes were examined in infants with preexisting medical diseases within the Canadian Registry Database (CARESS) to aid in developing guidelines for potential "at-risk" infants in the future. Infants who received ≥1 dose of palivizumab during the 2006-2010 respiratory syncytial virus (RSV) seasons at 29 sites were recruited and utilization, compliance, and outcomes related to respiratory infection/illness (RI) events were collected monthly. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for premature infants ≤35 completed weeks gestational age (GA) who met standard approval criteria (group 1) compared to those with medical disorders (group 2) using Cox proportional hazards regression models with adjustment for potential confounding factors. Of 7,339 registry infants, 4,880 were in group 1 and 952 in group 2, which included those with Down syndrome (20.3%), upper airway anomalies (18.7%), pulmonary diseases (13.3%), and cystic fibrosis (12.3%). Group 2 were older at enrollment (10.2 ± 9.2 vs. 3.5 ± 3.1 months, p < 0.0005), had higher GA (35.9 ± 6.0 vs. 31.0 ± 5.4 weeks, p < 0.0005), and were less compliant with treatment intervals (69.4% vs. 72.6%, p = 0.048). A greater proportion of group 2 infants were hospitalized for RI (9.0% vs. 4.2%, p < 0.0005) and RSV (2.4% vs. 1.3%, p = 0.003) (unadjusted). Being in group 2 was associated with an increased risk of RI (HR = 2.0, 95%CI 1.5-2.5, p < 0.0005), but not RSV hospitalization (HR = 1.6, 95% CI 0.9-2.8, p = 0.106). In infants receiving palivizumab, those with underlying medical disorders, though not currently approved for prophylaxis, are at higher risk for RI events compared with preterm infants. However, risk of RSV hospitalizations is similar.

Figures

Fig. 1
Fig. 1
Medical disorders comprising the special population group (group 2) over four RSV seasons (2006–2010). Dotted lines represent the overall percentages of each disorder subgroup
Fig. 2
Fig. 2
Cox proportional hazards model looking at time to first hospitalization (a) and first RSV hospitalization (b), comparing hazards for group 1 (solid line) and group 2 (dotted line)

References

    1. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalisations for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988;113:826–830. doi: 10.1016/S0022-3476(88)80008-8.
    1. American Academy of Pediatrics From the American Academy of Pediatrics: Policy statements—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694–1701. doi: 10.1542/peds.2009-1807.
    1. Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J. 1999;18:866–869. doi: 10.1097/00006454-199910000-00006.
    1. Bloemers BL, Broers CJ, Bont L, Weijerman ME, Gemke RJ, van Furth AM. Increased risk of respiratory tract infections in children with Down syndrome: the consequence of an altered immune system. Microbes Infect. 2010;12:799–808. doi: 10.1016/j.micinf.2010.05.007.
    1. Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, Kimpen JL, Bont L. High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection. Pediatr Infect Dis J. 2010;29:39–42. doi: 10.1097/INF.0b013e3181b34e52.
    1. Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, Kimpen JL, Strengers JL, Bont LJ. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis—a prospective birth-cohort study. Pediatrics. 2007;120:e1076–e1081. doi: 10.1542/peds.2007-0788.
    1. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184:350–354. doi: 10.1086/322043.
    1. Boyce TG, Mellen BG, Mitchel EF, Jr, Wright PF, Griffin MR. Rates of hospitalisation for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137:865–870. doi: 10.1067/mpd.2000.110531.
    1. Canadian Paediatric Society Infectious Diseases and Immunization Committee Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health. 1999;4:474–489.
    1. Canadian Paediatric Society Infectious Diseases and Immunization Committee. Langley JM. Use of palivizumab in children without congenital heart disease. Paediatr Child Health. 2003;8:631–636.
    1. Canadian Paediatric Society Infectious Diseases and Immunization Committee. Samson L. Prevention of respiratory syncytial virus infection. Paediatr Child Health. 2009;14:521–526.
    1. Carbonell-Estrany X, Lazaro y de Mercado P. Health economics and RSV. Paediatr Respir Rev. 2009;10(Suppl 1):12–13. doi: 10.1016/S1526-0542(09)70006-5.
    1. Cohen AH, Bomar R, Cohen LE, Lesnick B, Civgi V, Kirchner K, Graham L, Montgomery G, Scott P (2001) RSV prophylaxis using palivizumab in 86 high-risk children, outside AAP red book guidelines. American Pediatrics Scoeity/Society for Pediatric Research Annual Meeting, Baltimore, pp E-PAS2001:2656
    1. Cohen AH, Boron ML, Dingivan C (2005) A phase IV study of the safety of synagis (palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. International Conference of the American Thoracic Society, San Diego, Abstract A53
    1. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr, Connor EM, Sondheimer HM. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–540. doi: 10.1067/S0022-3476(03)00454-2.
    1. Figueras Aloy J, Carbonell Estrany X. Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation) An Pediatr (Barc) 2010;73:98 e91–98 e94.
    1. Frogel M, Nerwen C, Cohen A, Vanveldhuisen P, Harrington M, Boron M. Prevention of hospitalisation due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28:511–517. doi: 10.1038/jp.2008.28.
    1. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010;16:46–58.
    1. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol. 2008;43:169–174. doi: 10.1002/ppul.20751.
    1. Giusti R. North American synagis prophylaxis survey. Pediatr Pulmonol. 2009;44:96–98. doi: 10.1002/ppul.20922.
    1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917–1928. doi: 10.1056/NEJM200106213442507.
    1. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315:77–81. doi: 10.1056/NEJM198607103150201.
    1. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics. 1999;103:619–626. doi: 10.1542/peds.103.3.619.
    1. IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102:531–537. doi: 10.1542/peds.102.3.531.
    1. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215–1224. doi: 10.1086/514115.
    1. Lanctot KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Curr Med Res Opin. 2008;24:3223–3237. doi: 10.1185/03007990802484234.
    1. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med. 2002;96(Suppl B):S1–S7. doi: 10.1053/rmed.2002.1294.
    1. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, Majaesic C, Caouette G, Frenette L, Le Saux N, Simmons B, Moisiuk S, Sankaran K, Ojah C, Singh AJ, Lebel MH, Bacheyie GS, Onyett H, Michaliszyn A, Manzi P, Parison D. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalisation for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806–814. doi: 10.1097/.
    1. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, Brinch L, Brune M, De La Camara R, Dekker A, Pauksen K, Russell N, Schwarer AP, Cordonnier C. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28:479–484. doi: 10.1038/sj.bmt.1703139.
    1. Manzoni P, Leonessa ML, Galletto P, Gallo E, Sala U, Gomirato G, Farina D. Use of palivizumab in neonates who do not meet the American Academy of Pediatrics Guidelines for respiratory syncytial virus prophylaxis. Early Hum Dev. 2009;85:S93.
    1. McCormick J, Southern KW. A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child. 2007;92:87–88. doi: 10.1136/adc.2006.0105338.
    1. Michaels MG, Fonseca-Aten M, Green M, Charsha-May D, Friedman B, Seikaly M, Sanchez PJ. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant. 2009;13:451–456. doi: 10.1111/j.1399-3046.2008.01017.x.
    1. Mitchell I, Paes BA, Li A, Lanctot KL. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J. 2011;30:651–655. doi: 10.1097/INF.0b013e31821146f7.
    1. Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, Tsutsumi H, Yokota S, Itoh S. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother. 2010;17:254–263. doi: 10.1007/s10156-010-0121-1.
    1. Paes B, Manzoni P. Special populations: do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis? Early Hum Dev. 2011;87(Suppl 1):S55–S58. doi: 10.1016/j.earlhumdev.2011.01.012.
    1. Paes BA. Current strategies in the prevention of respiratory syncytial virus disease. Paediatr Respir Rev. 2003;4:21–27. doi: 10.1016/S1526-0542(02)00306-8.
    1. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev. 2009;10:148–153. doi: 10.1016/j.prrv.2009.06.003.
    1. Saez-Llorens X, Castano E, Null D, Steichen J, Sanchez PJ, Ramilo O, Top FH, Jr, Connor E. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:787–791. doi: 10.1097/00006454-199809000-00007.
    1. Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, Allen U, Mitchell I, Aloy JF, Pedraz C, Michaliszyn AF. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making. 2008;28:471–480. doi: 10.1177/0272989X08315238.
    1. Simoes EA. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res. 2002;3(Suppl 1):S26–S33. doi: 10.1186/rr187.
    1. Simoes EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res. 2008;9:78. doi: 10.1186/1465-9921-9-78.
    1. Speer ME, Fernandes CJ, Boron M, Groothuis JR. Use of palivizumab for prevention of hospitalisation as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J. 2008;27:559–561. doi: 10.1097/INF.0b013e3181673c15.
    1. Statistics Canada (2009) Quarterly demographic estimates: July to September 2009 (Catalogue # 91-002-X)
    1. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child. 2009;94:99–103. doi: 10.1136/adc.2008.139188.
    1. Van Ewijk BE, Wolfs TF, Aerts PC, Van Kessel KP, Fleer A, Kimpen JL, Van der Ent CK. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res. 2007;61:398–403. doi: 10.1203/pdr.0b013e3180332d1c.
    1. Welliver RC, Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalisations among high-risk and otherwise healthy children. Curr Med Res Opin. 2010;26:2175–2181. doi: 10.1185/03007995.2010.505126.
    1. Wilkesmann A, Ammann RA, Schildgen O, Eis-Hubinger AM, Muller A, Seidenberg J, Stephan V, Rieger C, Herting E, Wygold T, Hornschuh F, Groothuis JR, Simon A. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J. 2007;26:485–491. doi: 10.1097/INF.0b013e31805d01e3.
    1. Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med. 2002;96(Suppl B):S31–S35. doi: 10.1053/rmed.2002.1298.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir